|
시장보고서
상품코드
2117881
CGRP 저해제 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 적응증별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)CGRP Inhibitors Market Size, Share, and Growth Analysis, By Drug Type (Monoclonal Antibodies, Small Molecule CGRP Antagonists), By Indication, By Route of Therapy, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 CGRP 저해제 시장 규모는 2024년에 34억 달러로 평가되며, 2025년 37억 3,000만 달러에서 2033년까지 78억 3,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 9.7%로 성장할 것으로 전망되고 있습니다.
전 세계 CGRP 억제제 시장은 급속히 진화하고 있으며, 편두통 예방의 중요한 표적인 CGRP 경로를 억제하는 바이오의약품에 초점이 맞춰져 있습니다. 성인의 약 15%가 편두통을 경험하고 있다는 점을 감안할 때, 효과적이고 수용하기 쉬운 예방 치료에 대한 수요는 매우 높다고 할 수 있습니다. 이 시장은 기존의 저분자 의약품에서 특히 모노클로널 항체의 도입을 통해 보다 전문성이 높은 생물제제로 전환되고 있습니다. 보험사의 승인 확대와 환자 인식 제고에 힘입어 매출은 50억 달러를 넘어설 것으로 예측되며, 이러한 성장은 안전성과 유효성에 대해 보험사에 안도감을 주는 CGRP 모노클로널 항체의 승인으로 더욱 지원되고 있습니다. 자동 주사기 및 경구용 길항제를 포함한 투여 방식의 혁신에 더해, 12%를 상회할 것으로 예상되는 연평균 성장률(CAGR)은 전 세계 다양한 시장에서 편두통을 효과적으로 관리할 수 있는 유망한 전망을 보여주고 있습니다.
세계의 CGRP 억제제 시장의 성장 요인
편두통이 독자적인 신경질환이라는 인식이 높아짐에 따라 예방 치료의 대상이 되는 환자층이 확대되고 있습니다. 의료 종사자들은 현재 보다 정교한 진단 기준을 채택하고 있으며, CGRP 억제제의 혜택을 받을 수 있는 환자를 조기에 발견하는 데 기여하고 있습니다. 이러한 임상적 인식의 제고에 따라 의사들은 이러한 치료법을 처방할 때 더 큰 확신을 갖게 되었으며, 치료 프로토콜에 대한 도입이 진행되면서 일차 진료 및 전문 의료 분야 모두에서 수요가 확대되고 있습니다. 그 결과, 시장 관계자들은 편두통 관리를 위한 효과적인 해결책을 적극적으로 모색하는 환자층의 확대에 힘입어 판매량이 지속적으로 증가하는 것을 목격하고 있습니다.
전 세계 CGRP 억제제 시장의 제약 요인
CGRP 억제제에 수반되는 높은 비용은, 특히 의료 예산이 제한적인 지역에서 환자와 의료 서비스 제공자 모두에게 큰 과제가 되고 있습니다. 보험 환급 절차에서는 사전 승인이나 상세한 서류 제출이 빈번하게 요구되므로 치료가 지연되고, 의료 종사자들이 이러한 치료법을 권장하는 것을 주저하게 만드는 요인이 되고 있습니다. 그 결과, 이러한 치료의 혜택을 받아야 할 환자 중 일부는 치료를 받지 못한 채 남거나, 가격은 더 저렴하지만 효과는 떨어지는 대안을 고려할 수밖에 없는 경우도 있습니다. 이러한 가격에 대한 민감성은 시장 확대와 전반적인 발전을 현저히 저해하고 있으며, 제조사들은 가격에 대한 인식을 해소하고 복잡한 보험 환급 제도를 능숙하게 헤쳐 나가며 더 광범위한 수용을 촉진해야 하는 상황에 처해 있습니다.
전 세계 CGRP 억제제 시장의 동향
전 세계 CGRP 억제제 시장에서는 편두통의 예방적 관리로 패러다임이 전환되는 것을 특징으로 하는 혁신적인 동향이 나타나고 있습니다. 이러한 약물이 1차 치료제로 자리 잡음에 따라 신경과 전문의들은 환자의 삶의 질을 향상시키고 편두통 발작 빈도를 줄이기 위해 적극적으로 이를 처방하고 있습니다. 이러한 적극적인 접근 방식은 기존의 급성기 치료에 대한 의존을 최소화할 뿐만 아니라, 현대의 환자 중심 치료 목표 및 의료 보험사가 지속가능한 치료 성과를 중시하는 경향과도 부합합니다. CGRP 억제제의 안전성과 유효성에 대한 신뢰가 높아짐에 따라 다양한 의료 현장에서의 도입이 확대되고 있으며, 한편으로는 치료의 통합 및 복약 순응도를 강화하기 위한 노력도 시장 확대를 더욱 지원하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 CGRP 저해제 시장 규모 : 약제 유형별
세계의 CGRP 저해제 시장 규모 : 적응증별
세계의 CGRP 저해제 시장 규모 : 투여 경로별
세계의 CGRP 저해제 시장 규모 : 유통 채널별
세계의 CGRP 저해제 시장 규모 : 최종사용자별
세계의 CGRP 저해제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.27Global Cgrp Inhibitors Market size was valued at USD 3.4 Billion in 2024 and is poised to grow from USD 3.73 Billion in 2025 to USD 7.83 Billion by 2033, growing at a CAGR of 9.7% during the forecast period (2026-2033).
The global CGRP inhibitors market is rapidly evolving, focusing on biopharmaceuticals that inhibit the CGRP pathway, a critical target for migraine prevention. Given that nearly 15% of adults experience migraines, there is a significant demand for effective and acceptable preventive treatments. The market has transitioned from traditional small-molecule drugs to more specialized biologics, notably with the introduction of monoclonal antibodies. With projected revenues surpassing $5 billion driven by increasing acceptance from insurers and heightened patient awareness, growth is further supported by the endorsement of CGRP monoclonal antibodies, which reassures insurers regarding safety and efficacy. Innovations in delivery methods, including auto-injectors and oral antagonists, coupled with a forecasted compound annual growth rate above 12%, highlight a promising landscape for addressing migraine management effectively across diverse global markets.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cgrp Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cgrp Inhibitors Market Segments Analysis
Global cgrp inhibitors market is segmented by drug type, indication, route of therapy, distribution channel, end user and region. Based on drug type, the market is segmented into Monoclonal Antibodies, Small Molecule CGRP Antagonists, Combination Therapies and Others. Based on indication, the market is segmented into Episodic Migraine, Chronic Migraine, Cluster Headache and Others. Based on route of therapy, the market is segmented into Oral, Injectable, Intravenous and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Neurology Clinics, Specialty Headache Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cgrp Inhibitors Market
The growing acknowledgment of migraine as a unique neurological disorder has broadened the range of patients who qualify for preventive treatments. Healthcare professionals are now employing more precise diagnostic criteria, facilitating the early detection of individuals who could benefit from CGRP inhibitors. This increased clinical awareness enhances physician confidence in prescribing these therapies, prompting their integration into treatment protocols and boosting demand in both primary care and specialized medical contexts. Consequently, market players are witnessing continuous volume growth, supported by an expanding patient population actively seeking effective solutions for migraine management.
Restraints in the Global Cgrp Inhibitors Market
The high cost associated with CGRP inhibitors presents a formidable challenge for both patients and healthcare providers, particularly in areas where healthcare funding is limited. Reimbursement protocols frequently necessitate prior approvals and detailed documentation, resulting in treatment delays and dissuading healthcare professionals from recommending these therapies. As a result, some individuals who would benefit from these treatments either go without them or are forced to consider more affordable, yet less effective options. This sensitivity to pricing significantly impedes market expansion and overall development, compelling manufacturers to tackle pricing perceptions and maneuver through intricate reimbursement systems to foster wider acceptance.
Market Trends of the Global Cgrp Inhibitors Market
The global CGRP inhibitors market is witnessing a transformative trend characterized by a paradigm shift towards preventive migraine management. As these agents gain traction as first-line therapies, neurologists are proactively prescribing them to enhance patient quality of life and decrease migraine frequency. This proactive approach not only minimizes the dependence on conventional acute treatments but also aligns with modern patient-centered care goals and healthcare payers' focus on sustainable outcomes. Growing confidence in the safety and efficacy of CGRP inhibitors is driving their increased adoption across various healthcare settings, while initiatives to bolster treatment integration and adherence further support market expansion.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global CGRP Inhibitors Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Monoclonal Antibodies
- Small Molecule CGRP Antagonists
- Combination Therapies
- Others
Global CGRP Inhibitors Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Episodic Migraine
- Chronic Migraine
- Cluster Headache
- Others
Global CGRP Inhibitors Market Size by Route of Therapy & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
- Intravenous
- Others
Global CGRP Inhibitors Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Others
Global CGRP Inhibitors Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Neurology Clinics
- Specialty Headache Centers
- Others
Global CGRP Inhibitors Market Size & CAGR (2026-2033)
- North America (Drug Type, Indication, Route of Therapy, Distribution Channel, End User)
- US
- Canada
- Europe (Drug Type, Indication, Route of Therapy, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Type, Indication, Route of Therapy, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Type, Indication, Route of Therapy, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Indication, Route of Therapy, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lundbeck A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biohaven Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organon & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
